Discovery and validation an eight-biomarker serum gene signature for the diagnosis of steroid-induced osteonecrosis of the femoral head

Inferences of individual differences in response to tripterysium glycosides across patients with Rheumatoid arthritis using a novel ceRNA regulatory axis

“…The above data confirmed the pharmacological actions of TGT against RA based on the CIA mouse model. Among the three dosages (13,26, and 52 mg/kg), we found that the antiarthritis effects of 26 mg/kg TGT (CIA-TGT-2 group) were similar to that of 52 mg/kg TGT (CIA-TGT-4 group), which showed the obvious toxicity such as the decreased body weight of CIA mice in CIA-TGT-4 group ( Figure 4D). Therefore, the CIA-TGT-2 group was selected for the following studies.…”

“…Following the verification of the associations of the ceRNA axis with TGT response, PLS models for predicting the RA patients' response to TGT and CIA mice were constructed using the RNA expression data of the ceRNA axis in peripheral blood as described previously 11,13 . The independent dataset test was performed to evaluate the performance of our TGT‐response prediction model based on the average accuracy and area‐under‐curve (AUC) of the receiver‐operating‐characteristic (ROC) curves calculated as our description in the previous studies 11,13 …”

“…11,13 The independent dataset test was performed to evaluate the performance of our TGT-response prediction model based on the average accuracy and area-under-curve (AUC) of the receiver-operating-characteristic (ROC) curves calculated as our description in the previous studies. 11,13…”

<p>Inflammation, Bone Healing and Osteonecrosis: From Bedside to Bench</p>

“…35 In a study in which serum was collected from 20 patients with various stages of ONFH and compared with serum from normal controls, eight genes, including TLR4 were identified as potential serum biomarkers of the disease. 36 The other biomarkers including BIRC3, CBL, CCR5, LYN, PAK1, PTEN, and RAF1 were related to inflammation, bone and cartilage metabolism, and vasculogenesis. This suggests that potential biological strategies to mitigate the adverse sequelae of osteonecrosis might entail curtailing chronic inflammation, and facilitating bone formation and vasculogenesis.…”

PTEN inhibitor VO-OHpic attenuates GC-associated endothelial progenitor cell dysfunction and osteonecrosis of the femoral head via activating Nrf2 signaling and inhibiting mitochondrial apoptosis pathway

“…Inhibition of PTEN with VO-OHpic could attenuate apoptosis and cardiac remodeling in doxorubicin-induced cardiomyopathy [17]. Interestingly, a recent study identified that PTEN was significantly elevated in GC-associated ONFH patients and was identified as a candidate serum biomarker for these patients [18]. We are especially interested in whether direct inhibition of PTEN with VO-OHpic could protect the EPCs from GC-induced damage and further whether VO-OHpic could protect the blood supply in the femoral head of GC-associated ONFH in rats.…”